CREVF (CREVF) Stock Price & Analysis
CREVF (CREVF) rose 0.00% to USD 0 as of September 9, 2026 at 13:21 UTC, according to Nexqual real-time market data.
CREVF last closed at USD 0; the session ranged USD 0.01–0.03 on volume of 2,032 shares. Market capitalization is —, with a 52-week range of USD 0–7.24 (PNK). Source: Nexqual, September 9, 2026 at 13:21 UTC.
Key Statistics (as of September 9, 2026 at 13:21 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0.01 – 0.03 |
| 52-Week Range | USD 0 – 7.24 |
| Volume | 2,032 shares |
| Market Cap | — |
| Exchange | PNK |
Technical Analysis (CREVF)
Nexqual's technical model rates CREVF "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of September 9, 2026 at 13:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Leadership (CREVF)
CREVF is led by Donald Hampton, CEO & Director, per Nexqual as of September 9, 2026 at 13:21 UTC.
| CEO & Director | Donald Hampton |
|---|---|
| Chief Financial Officer | Gerard Buckle |
| Founder & CTO | Ashley James Denmead |
| Director of People & Culture | Laura Neville |
| Chief Revenue Officer | Alia Comai |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGLC | BioNexus Gene Lab Corp | USD 1.4 | ▼ 4.76% |
| BENF | Beneficient | USD 1.8 | ▼ 16.51% |
| APLM | Apollomics Inc. | USD 24.5 | ▼ 12.53% |
| ZAPPF | Zapp Electric Vehicles Group Li | USD 0 | ▲ 0% |
| BBLG | Bone Biologics Corp | USD 0.56 | ▲ 0.38% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 13:21 UTC. This page is informational and not investment advice.